

Nerelimomab

Cat. No.:	HY-P99753
CAS No.:	162774-06-3
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Nerelimomab (BAYX1351) is an anti-TNF- α antibody. Nerelimomab can be used for research of sepsis ^{[1][2]} .	
In Vivo	Nerelimomab (7.5 mg/kg, i.v. infusion) protected animals from death in a baboon model of recurrent bacteremia ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Baboon model of recurrent bacteremia (Challenged with E.coli) ^[1]
	Dosage:	7.5 mg/kg
	Administration:	i.v. infusion
	Result:	Improved organ function and attenuated cytokine and plasminogen activator inhibitor release.

REFERENCES

[1]. Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22.

[2]. Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA